Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Dec;11(12):923–930. doi: 10.1631/jzus.B1000125

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © Zhejiang University and Springer-Verlag Berlin Heidelberg 2010

PMC Copyright notice

Fig. 3 — Fatty acid compositions of HUVEC (a), LoVo (b), and Rko (c) cells

Sum(SFA): percent of saturated fatty acids in cell total fatty acids, including tetradecanoate (C14:0), hexadecanoic acid (C16:0), octadecanoic acid (C18:0), eicosanoic acid (C20:0), and docosanoic acid (C22:0); Sum(n-9): percent of n-9 fatty acids in cell total fatty acids, including 9-hexadecenoic acid (C16:1), 9-octadecenoic acid (C18:1), and 9-eicosenoic acid (C20:1); Sum(n-6): percent of n-6 fatty acids in cell total fatty acids, including 9,12-octadecadienoic acid (C18:2), 5,8,11,14-eicosatetraenoic acid (C20:4), 11,14-eicosadienoic acid (C20:2), and 5,11,14,17-eicosatetraenoate (C22:4); Sum(n-3): percent of n-3 fatty acids in cell total fatty acids, including 11,14,17-linolenic acid (C18:3), 5,8,11,14,17-eicosapentaenoic acid (C20:5), and 4,7,10,13,16,19-docosahexaenoic acid (C22:6). CK: case-control with medium; NaOH: case-control with 0.1 mol/L NaOH. For LoVo and Rko cells, A: 100 µmol/L without LA pre-treatment, B: 300 µmol/L without LA pre-treatment, C: 100 µmol/L with 100 µmol/L LA pre-treatment, D: 300 µmol/L with 100 µmol/L LA pre-treatment; for HUVEC, A: 200 µmol/L without LA pre-treatment, B: 400 µmol/L without LA pre-treatment, C: 200 µmol/L with 100 µmol/L LA pre-treatment, D: 400 µmol/L with 100 µmol/L LA pre-treatment. Data are expressed as mean±SD (n=3)

Fig. 3 — Fatty acid compositions of HUVEC (a), LoVo (b), and Rko (c) cells

Sum(SFA): percent of saturated fatty acids in cell total fatty acids, including tetradecanoate (C14:0), hexadecanoic acid (C16:0), octadecanoic acid (C18:0), eicosanoic acid (C20:0), and docosanoic acid (C22:0); Sum(n-9): percent of n-9 fatty acids in cell total fatty acids, including 9-hexadecenoic acid (C16:1), 9-octadecenoic acid (C18:1), and 9-eicosenoic acid (C20:1); Sum(n-6): percent of n-6 fatty acids in cell total fatty acids, including 9,12-octadecadienoic acid (C18:2), 5,8,11,14-eicosatetraenoic acid (C20:4), 11,14-eicosadienoic acid (C20:2), and 5,11,14,17-eicosatetraenoate (C22:4); Sum(n-3): percent of n-3 fatty acids in cell total fatty acids, including 11,14,17-linolenic acid (C18:3), 5,8,11,14,17-eicosapentaenoic acid (C20:5), and 4,7,10,13,16,19-docosahexaenoic acid (C22:6). CK: case-control with medium; NaOH: case-control with 0.1 mol/L NaOH. For LoVo and Rko cells, A: 100 µmol/L without LA pre-treatment, B: 300 µmol/L without LA pre-treatment, C: 100 µmol/L with 100 µmol/L LA pre-treatment, D: 300 µmol/L with 100 µmol/L LA pre-treatment; for HUVEC, A: 200 µmol/L without LA pre-treatment, B: 400 µmol/L without LA pre-treatment, C: 200 µmol/L with 100 µmol/L LA pre-treatment, D: 400 µmol/L with 100 µmol/L LA pre-treatment. Data are expressed as mean±SD (n=3)